Bio-Techne Stock Slides -6.3% With A 5-Day Losing Spree
Bio-Techne (TECH) stock hit day 5 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -6.3% return. The company has lost about $599 Mil in value over the last 5 days, with its current market capitalization at about $8.9 Bil. The stock remains 20.0% below its value at the end of 2024. This compares with year-to-date returns of 14.4% for the S&P 500.
Bio-Techne’s recent streak saw its shares pressured following Q1 fiscal 2026 results. Despite meeting adjusted EPS, revenue fell 1% to $286.6 million, missing analyst targets and sparking a pre-market drop. Persistent funding headwinds for emerging biotech companies, alongside a North American revenue dip, weighed heavily on investor sentiment. For quick background: TECH provides life science reagents, instruments, and diagnostic products for research, diagnostics, and cell and gene therapy applications.
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Our take: There are a few things to fear in TECH stock given its overall Moderate operating performance and financial condition. But keeping in mind its High valuation, we think that the stock is Unattractive. Deep dive with Buy or Sell TECH.
Individual stocks can soar or tank but one thing matters: staying invested. High Quality Portfolio helps you do that.
Comparing TECH Stock Returns With The S&P 500
The following table summarizes the return for TECH stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | TECH | S&P 500 |
|---|---|---|
| 1D | -1.3% | 0.1% |
| 5D (Current Streak) | -8.2% | -1.6% |
| 1M (21D) | -4.2% | -0.1% |
| 3M (63D) | 14.5% | 5.6% |
| YTD 2025 | -20.0% | 14.4% |
| 2024 | -6.2% | 23.3% |
| 2023 | -6.5% | 24.2% |
| 2022 | -35.6% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 72 S&P constituents with 3 days or more of consecutive gains and 23 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 42 | 8 |
| 4D | 22 | 6 |
| 5D | 5 | 7 |
| 6D | 1 | 1 |
| 7D or more | 2 | 1 |
| Total >=3 D | 72 | 23 |
Key Financials for Bio-Techne (TECH)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $1.2 Bil | $1.2 Bil |
| Operating Income | $246.4 Mil | $242.8 Mil |
| Net Income | $168.1 Mil | $73.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $317.0 Mil | $286.6 Mil |
| Operating Income | $116.7 Mil | $47.7 Mil |
| Net Income | $-17.7 Mil | $38.2 Mil |
The losing streak TECH stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.